These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34593162)

  • 1. Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective.
    Kennedy C; McCullagh L; Adams R; Trela-Larsen L; Tilson L; Barry M
    Value Health; 2021 Oct; 24(10):1402-1406. PubMed ID: 34593162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
    McCullagh L; Schmitz S; Barry M; Walsh C
    Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and reimbursement of drugs in Ireland.
    Barry M; Tilson L; Ryan M
    Eur J Health Econ; 2004 Jun; 5(2):190-4. PubMed ID: 15452757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Price of Substitute Technologies.
    Santos AS; Guerra-Junior AA; Noronha KVMS; Andrade MV; Ruas CM
    Value Health Reg Issues; 2019 Dec; 20():154-158. PubMed ID: 31561148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability.
    Almajed S; Alotaibi N; Zulfiqar S; Dhuhaibawi Z; O'Rourke N; Gaule R; Byrne C; Barry AM; Keeley D; O'Mahony JF
    Eur J Health Econ; 2022 Apr; 23(3):375-431. PubMed ID: 34460007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
    Hsieh CR; Sloan FA
    Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System.
    Soares Santos A; de Souza Noronha KVM; Viegas Andrade M; Mariano Ruas C
    J Ment Health Policy Econ; 2020 Mar; 23(1):27-37. PubMed ID: 32458815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic evaluation in Ireland: a review of the process.
    Tilson L; O'Leary A; Usher C; Barry M
    Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
    McCullagh L; Walsh C; Barry M
    Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.